Effects of imiglucerase or velaglucerase to quantify enzyme activity in patients with Gaucher disease type 1

Trial Profile

Effects of imiglucerase or velaglucerase to quantify enzyme activity in patients with Gaucher disease type 1

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Imiglucerase (Primary) ; Velaglucerase alfa (Primary)
  • Indications Gaucher's disease type I
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Apr 2016 New trial record
    • 15 Apr 2016 Results published in the Clinical Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top